The following are older news articles. We thought that you may still find them useful.
Tumor Suppressor Role of Notch-1 Signaling in Neuroendocrine Tumors
(full text)
Muthusamy Kunnimalayaan, Herbert Chen
Endocrine Surgery Research Laboratories, Department of Surgery, The University of Wisconsin, and the University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin,
USA
The Oncologist 2007;12:535/542
ABSTRACT
A growing body of literature is demonstrating that Notch signaling is a more complex process than originally thought. Contradictory findings of notch-1 acting as an oncogene or a tumor suppressor revealed that its role is very specific to the cellular context. In this review we focus on the tumor suppressor role of Notch-1 signaling in neuroendocrine tumors (NETs) such as carcinoid and medullary thyroid cancers. NETs secrete various bioactive hormones that can cause debilitating symptoms. Surgery is the only potential curative treatment for the patients with NETs. Notch-1 signaling is absent in these tumors and activation of Notch-1 significantly
reduces tumor growth in vitro. Therefore, identification
of compound(s) that activate the Notch-1 pathway in NETs could be a potential strategy to treat patients with NETs.
BACKGROUND: We have shown previously that activation of the Raf-1/mitogen-activated protein kinase (MEK)/extracellular signal-regulated kinase (ERK)1/2 signaling pathway by ZM336372 inhibits carcinoid cells growth. In the present study, we further characterize the molecular details of the growth inhibition by the signaling-based compound ZM336372 in neuroendocrine neoplasms (NENs). METHODS: NEN cells were treated with ZM336372 (20 to 100 mumol/L) or carrier (DMSO). Western Blot was used to determine the activation of the Raf-1/MEK/ERK, other pathways activation, and cellular bioactive hormone production.
CONCLUSION: This is the first description of a novel compound ZM336372 that regulates multiple pathways in NEN cells.
Andrew S. Kennedy; Richard Warner, Patrick McNeillie, William A. Dezarnl, Doug Coldwell, Charles Nutting , Dennis Carter, avi Murthy, Steven Rose, David Liu, Carroll Overton, Riad Salem
Cancer Investigation, 25(S 1):55-56,2007
ISSN: 0735-7907 print/ 1532-4192 online
Recommendations for radioembolization of hepatic malignancies using Yttrium-90 microsphere brachytherapy.
A consensus panel report from the radioembolization brachytherapy oncology consortium
Int. J. Radiation Oncology Biol. Phys., Vol. 68, No. 1, pp. 13–23, 2007 Full Text
PURPOSE: To standardize the indications, techniques, multimodality treatment approaches, and dosimetry to be used for yttrium-90 (Y90) microsphere hepatic brachytherapy.
METHODS AND MATERIALS: Members of the Radioembolization Brachytherapy Oncology Consortium met as an independent group of experts in interventional radiology, radiation oncology, nuclear medicine, medical oncology, and surgical oncology to identify areas of consensus and controversy and to issue clinical guidelines for Y90 microsphere brachytherapy.therapies.
CONCLUSIONS: Yttrium-90 microsphere therapy is a complex procedure that requires multidisciplinary management for safety and success. Practitioners and cooperative groups are encouraged to use these guidelines to formulate their treatment and dose-reporting policies.
IMPROVING WORLDWIDE CANCER CARE AND
PREVENTION AWARENESS Oncology by OncologyStat Elsevier’s Oncologystat.com recently upgraded its website.
OncologySTAT's mission is to improve worldwide cancer care and prevention by providing healthcare professionals with immediate integrated access to the most authoritative evidence-based information available. OncologySTAT’s commitment to international health ensures that news, research, education, and analysis from all regions of the world are covered in a publisher, society, and sponsor-neutral online environment.
TIP: for example, type"carcinoid tumors all sites" (or other cancers) in the advanced search window and you will receive a comprehensive list of up-to-date peer-review articles of carcinoid tumors from over 100 Elsevier cancer-related journals, including The Lancet Oncology, The Breast, Lung Cancer, The American Journal of Medicine, Cancer Letters, etc. Many articles are full text.
Population-based study of islet cell carcinoma
Yao JC, Eisner MP, Leary C, Dagohoy C, Phan A, Rashid A, Hassan M, Evans DB. Department of Gastrointestinal Medical Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA. jyao@mdanderson.org
Ann Surg Oncol. 2007 Dec;14(12):3492-500. Epub 2007 Sep 26.
CONCLUSION: Patients with malignant pancreatic neuroendocrine tumors commonly present with advanced disease. Although, curative resection is not frequent, survival benefit may be obtainable with aggressive surgical management even in the face of metastatic disease.
Note: Acknowledgments Supported by gifts from Raymond Sackler, the J. Stuart Foundation, and the Carcinoid Cancer Foundation.
"US Pet Scan" Progress Notes July 2007
Letter from
Stanley J. Goldsmith, MD
Director of Nuclear Medicine
Professor of Radiology and Medicine
New York Presbyterian Hospital-Well Cornell Medical Center
New York, NY
Progress Notes February 26, 2006:
The first of its kind in North America, the 11C-5-HTP-PET scan also known to the carcinoid community as the PET SCAN PROJECT (not to be confused with the standard FDG PET scan) is now in clinical trials since December 2005. We are happy to announce that the scan IS WORKING and the first results from the ongoing trials was presented at the Carcinoid Cancer Foundation's patient symposium on April 2 at Mount Sinai Hospital in New York City. Due to the generosity of hundreds of members of the carcinoid community from coast to coast, with a matching grant from The Carcinoid Cancer Foundation, a new 11C-5-HTP-PET scan will be available for the first time in the United States. A total of $30,000 enabled Shankar Vallabhajosula, Ph.D., chief of radiochemistry at Cornell University's Weill Medical College, Citigroup Biomedical Imaging Center (CBIC), to officially begin a research project entitled Synthesis of [11C] 5-Hydroxy Tryptophan (HTP)in December 2004 (See for more information).
Cancer Survivor Takes on Vital Mission
Published by the North Jersey Media Group Inc. June 6, 2004
Judy Golz, a carcinoid survivor , of New Jersey said "carcinoid cancer has redefined her life."
"I'm very aware of life and making memories," she said. "I'm a stronger person and have more purpose. I may succumb to this disease, but the legacy I need to leave to my children is that I did everything I could to help myself and others."
